New hope for arthritis sufferers: filgotinib shows promise in korean trial
NCT ID NCT06625242
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug filgotinib (Jyseleca) in 118 Korean adults with rheumatoid arthritis. The goal was to see how many patients experienced at least a 20% improvement in symptoms after 12 weeks of treatment. The trial is complete, and results will help determine if filgotinib is a safe and effective option for this population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
filgotinib (Jyseleca)
What this could lead to
If successful, this could confirm filgotinib as a safe and effective option for controlling rheumatoid arthritis symptoms in Korean patients.
What could go wrong
This is a single-arm, open-label study with no placebo group, so results may be less reliable. It is also limited to Korean patients, so findings may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Eisai site #01
Busan, South Korea
-
Eisai site #02
Gwangju, South Korea
-
Eisai site #03
Seoul, South Korea
-
Eisai site #04
Seoul, South Korea
-
Eisai site #05
Seoul, South Korea
-
Eisai site #06
Daejeon, South Korea
-
Eisai site #07
Seoul, South Korea
-
Eisai site #08
Seoul, South Korea
-
Eisai site #09
Daegu, South Korea
-
Eisai site #10
Seoul, South Korea
-
Eisai site #11
Anyang-si, South Korea
-
Eisai site #12
Daegu, South Korea
-
Eisai site #13
Incheon, South Korea
-
Eisai site #14
Seoul, South Korea
-
Eisai site #15
Guri-si, South Korea